Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Zoetis Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $94.98, while Zoetis Inc trades at $73 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EMB | ZTS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $156.76 |
52-Week Low | $92.95 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $94.99 with minimal daily movement (+0.16%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces significant selling pressure with support and resistance clustered around $95. Recent corporate actions include scheduled dividend payments through mid-2026, though key financial ratios remain undisclosed in current filings.
The outlook remains cautious with technical indicators favoring sellers and limited fundamental data available. Investment opportunity centers on dividend income stream, while risks include emerging market sovereign default exposure and Federal Reserve policy sensitivity. Analyst sentiment suggests limited upside potential beyond current yield returns.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
